Fibrates in the chemical action of daunorubicin

Current Cancer Drug Targets

Volumn 9, Issue 3, 2009, Pages 366-369

  Balendiran, Ganesaratnam K ^a  

^a YOUNGSTOWN STATE UNIVERSITY   (United States)

Author keywords

AKR; AKR1B10; Cancer; Daunorubicin; Fibrate

Indexed keywords

ANTHRACYCLINE; CIPROFIBRATE; DAUNORUBICIN; FENOFIBRATE; FENOFIBRIC ACID; FIBRIC ACID DERIVATIVE; OXIDOREDUCTASE; PIRINIXIC ACID; PROTEIN AKR1B10; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ARTICLE; BREAST TUMOR; CARDIOMYOPATHY; CHILDHOOD CANCER; CONGESTIVE HEART FAILURE; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; GENE EXPRESSION; HEART INJURY; HUMAN; HYPERGLYCEMIA; LEUKEMIA; LIPID PEROXIDATION; LUNG CANCER; LUNG TUMOR; LYMPHOMA; OVARY TUMOR; SARCOMA; SOLID TUMOR; UPREGULATION;

ALDEHYDE REDUCTASE; ANTIBIOTICS, ANTINEOPLASTIC; CLOFIBRIC ACID; DAUNORUBICIN; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KINETICS; MODELS, MOLECULAR; NEOPLASMS; SUBSTRATE SPECIFICITY;

EID: 65649142907     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800909788166538     Document Type: Article

References (39)

1. Balendiran, G. K.; Verma, M.; Perry, E. Chemistory of Fibrates. Curr. Chem. Biol. 2007, 1, 311-316.
2. Balendiran, G. K.; Martin, H. J.; El-Hawari, Y.; Maser, E. Cancer biomarker AKR1B10 and carbonyl metabolism. Chem. Biol. Interact. 2009, 178, 134-137.
3. Verma, M.; Martin, H. -J.; Haq, W.; O'Connor, T. R.; Maser, E.; Balendiran, G. K. Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers. Eur. J. Pharm. 2008, 584, 213-221.
4. Martin, H. J.; Breyer-Pfaff, U.; Wsol, V.; Venz, S.; Block, S.; Maser, E. Purification and characterization of akr1b10 from human liver: role in carbonyl reduction of xenobiotics. Drug Metab. Dispos. 2006, 34, 464-470. (Pubitemid 43290905)
5. Arcamone, F.; Franceschi, G.; Orezzi, P.; Cassinelli, G.; Barbieri, W.; Mondelli, R. Daunomycin. I. The structure of daunomycione. J. Am. Chem. Soc. 1964, 86, 5334-5335.
6. Arcamone, F.; Franceschi, G.; Penco, S.; Selva, A. Adridmycin (14-hydroxydaunomycin), a novel antitumor antibiotic. Tetrahedron Lett. 1969, 13, 1007-1010.
7. Dimarco, A.; Gaetani, M.; Orezzi, P.; Scarpinato, B. M.; Silvestrini, R.; Soldati, M.; Dasdia, T.; Valentini, L. 'Daunomycin', A New Antibiotic Of The Rhodomycin Group. Nature 1964, 201, 706-707.
8. Wang, J. C. Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell Biol. 2002, 3, 430-440. (Pubitemid 34685700)
9. Pommier, Y.; Pourquier, P.; Fan, Y.; Strumberg, D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim. Biophys. Acta 1998, 1400, 83-105.
10. Nitiss, J. L. Roles of DNA topoisomerases in chromosomal replication and segregation. Adv. Pharmacol. 1994, 29A, 103-134.
11. Liu, L. F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 1989, 58, 351-375. (Pubitemid 19172974)
12. Froelich-Ammon, S. J.; Osheroff, N. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J. Biol. Chem. 1995, 270, 21429-21432.
13. Capranico, G.; Binaschi, M.; Borgnetto, M. E.; Zunino, F.; Palumbo, M. A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poisons. Trends Pharmacol. Sci. 1997, 18, 323-329. (Pubitemid 27404659)
14. Wang, J. C. DNA topoisomerases. Annu. Rev. Biochem. 1996, 65, 635-692. (Pubitemid 26250622)
15. Fukumoto, S.; Yamauchi, N.; Moriguchi, H.; Hippo, Y.; Watanabe, A.; Shibahara, J.; Taniguchi, H.; Ishikawa, S.; Ito, H.; Yamamoto, S., et al. Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas. Clin. Cancer Res. 2005, 11, 1776-1785. (Pubitemid 40471839)
16. Jez, J. M.; Flynn, T. G.; Penning, T. M. A new nomenclature for the aldo-keto reductase superfamily. Biochem. Pharmacol. 1997, 54, 639-647. (Pubitemid 27404623)
17. Cao, D.; Fan, S. T.; Chung, S. S. Identification and characterization of a novel human aldose reductase-like gene. J. Biol. Chem. 1998, 273, 11429-11435. (Pubitemid 28272034)
18. Hyndman, D. J.; Flynn, T. G. Sequence and expression levels in human tissues of a new member of the aldo-keto reductase family. Biochim. Biophys. Acta 1998, 1399, 198-202. (Pubitemid 28410465)
19. Scuric, Z.; Stain, S. C.; Anderson, W. F.; Hwang, J. J. New member of aldose reductase family proteins overexpressed in human hepatocellular carcinoma. Hepatology 1998, 27, 943-950. (Pubitemid 28160478)
20. Yoshitake, H.; Takahashi, M.; Ishikawa, H.; Nojima, M.; Iwanari, H.; Watanabe, A.; Aburatani, H.; Yoshida, K.; Ishi, K.; Takamori, K., et al. Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer. Int. J. Gynecol. Cancer 2007, 17, 1300-1306. (Pubitemid 350077355)
21. Ma, J.; Yan, R.; Zu, X.; Cheng, J. M.; Rao, K.; Liao, D. F.; Cao, D. Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-coa carboxylase-alpha in breast cancer cells. J. Biol. Chem. 2008, 283, 3418-3423.
22. Kim, B.; Lee, H. J.; Choi, H. Y.; Shin, Y.; Nam, S.; Seo, G.; Son, D. S.; Jo, J.; Kim, J.; Lee, J., et al. Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data. Cancer Res. 2007, 67, 7431-7438. (Pubitemid 47206573)
23. Yan, R.; Zu, X.; Ma, J.; Liu, Z.; Adeyanju, M.; Cao, D. Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention. Int. J. Cancer 2007, 121, 2301-2306. (Pubitemid 47585613)
24. Tanaka, M.; Bateman, R.; Rauh, D.; Vaisberg, E.; Ramachandani, S.; Zhang, C.; Hansen, K. C.; Burlingame, A. L.; Trautman, J. K.; Shokat, K. M.; et al. An unbiased cell morphology-based screen for new, biologically active small molecules. PLoS Biol. 2005, 3, e128.
25. Ax, W.; Soldan, M.; Koch, L.; Maser, E. Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochem. Pharmacol. 2000, 59, 293-300. (Pubitemid 30001756)
26. Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004, 56, 185-229. (Pubitemid 38720829)
27. Olson, L. E.; Bedja, D.; Alvey, S. J.; Cardounel, A. J.; Gabrielson, K. L.; Reeves, R. H. Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1. Cancer Res. 2003, 63, 6602-6606. (Pubitemid 37336434)
28. Mordente, A.; Minotti, G.; Martorana, G. E.; Silvestrini, A.; Giardina, B.; Meucci, E. Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications. Biochem. Pharmacol. 2003, 66, 989-998. (Pubitemid 37086708)
29. Safra, T. Cardiac safety of liposomal anthracyclines. Oncologist 2003, 8(Suppl. 2), 17-24. (Pubitemid 37152053)
30. Swain, S. M.; Whaley, F. S.; Ewer, M. S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003, 97, 2869-2879. (Pubitemid 36605157)
31. Burke, B. E.; Mushlin, P. S.; Cusack, B. J.; Olson, S. J.; Gambliel, H. A.; Olson, R. D. Decreased sensitivity of neonatal rabbit sarcoplasmic reticulum to anthracycline cardiotoxicity. Cardiovasc. Toxicol. 2002, 2, 41-51. (Pubitemid 37070571)
32. Maluf, F. C.; Spriggs, D. Anthracyclines in the treatment of gynecologic malignancies. Gynecol. Oncol. 2002, 85, 18-31. (Pubitemid 34304005)
33. Hortobagyi, G. N. Anthracyclines in the treatment of cancer. An overview. Drugs 1997, 54(Suppl. 4), 1-7. (Pubitemid 27487789)
34. Legha, S. S.; Benjamin, R. S.; Mackay, B.; Ewer, M.; Wallace, S.; Valdivieso, M.; Rasmussen, S. L.; Blumenschein, G. R.; Freireich, E. J. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann. Intern. Med. 1982, 96, 133-139. (Pubitemid 12172323)
35. Miller, D. B.; Spence, J. D. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin. Pharmacokinet. 1998, 34, 155-162. (Pubitemid 28077673)
36. Forcheron, F.; Cachefo, A.; Thevenon, S.; Pinteur, C.; Beylot, M. Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients. Diabetes 2002, 51, 3486-3491. (Pubitemid 35403454)
37. Jones, I. R.; Swai, A.; Taylor, R.; Miller, M.; Laker, M. F.; Alberti, K. G. Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM. Diabetes Care 1990, 13, 855-863. (Pubitemid 20331540)
38. Fruchart, J. C.; Brewer, H. B., Jr.; Leitersdorf, E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. Am. J. Cardiol. 1998, 81, 912-917. (Pubitemid 28204644)
39. Rubins, H. B.; Robins, S. J.; Collins, D.; Fye, C. L.; Anderson, J. W.; Elam, M. B.; Faas, F. H.; Linares, E.; Schaefer, E. J.; Schectman, G.; et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 1999, 341, 410-418.